South Coast Retina Center, Long Beach, California.
Wills Eye Hospital, Mid Atlantic Retina, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania.
Ophthalmology. 2021 Sep;128(9):1266-1273. doi: 10.1016/j.ophtha.2021.04.021. Epub 2021 Apr 22.
To determine the rate and risk factors for new persistent opioid use after ophthalmic surgery in the United States.
Retrospective claims-based cohort analysis.
Opioid-naive patients 13 years of age and older who underwent incisional ophthalmic surgery between January 1, 2012, and June 30, 2017, and were included in Optum's de-identified Clinformatics Data Mart database.
New persistent opioid use was defined as filling an opioid prescription in the 90-day and the 91- to 180-day periods after the surgical procedure. The outcome variable was an initial perioperative opioid prescription fill. Rates of new persistent opioid use were calculated, and multivariate logistic regression models were used to identify variables increasing the risk of new persistent use and refill of an opioid prescription after the initial perioperative prescription in first 30 days.
New persistent opioid use and refill.
A total of 327 379 opioid-naive patients (mean age, 67 years [standard deviation, 16 years]; 178 067 women [54.4%]) who underwent ophthalmic surgery were examined. Among these patients, 14 841 (4.5%) had an initial perioperative opioid fill. The rate of new persistent opioid use was 3.4% (498 of 14 841 patients) compared with 0.6% (1833 of 312 538 patients) in patients who did not have an initial perioperative opioid fill. After adjusting for patient characteristics, initial perioperative opioid fill was associated independently with increased odds of new persistent use (adjusted odds ratio [OR], 6.21; 95% confidence interval [CI], 5.57-6.91; P < 0.001). Among patients who had filled an initial perioperative prescription, a prescription size of 150 morphine milligram equivalents or more was associated with an increased odds of refill (adjusted OR, 1.87; 95% CI, 1.58-2.22; P < 0.001).
Exposure to opioids in the perioperative period is associated with new persistent use in patients who were previously opioid-naive. This suggests that exposure to opioids is an independent risk factor for persistent use in patients undergoing incisional ophthalmic surgery. Surgeons should be aware of those risks to identify at-risk patients given the current national opioid crisis and to minimize prescribing opioids when possible.
在美国,确定眼科手术后新的持续性阿片类药物使用的发生率和风险因素。
回顾性基于索赔的队列分析。
2012 年 1 月 1 日至 2017 年 6 月 30 日期间接受切口性眼科手术且年龄在 13 岁及以上的阿片类药物初治患者,这些患者均纳入 Optum 去识别 Clinformatics Data Mart 数据库。
新的持续性阿片类药物使用定义为在手术 90 天和 91-180 天期间开具阿片类药物处方。主要结局变量为围手术期初始阿片类药物处方的首次配药。计算新的持续性阿片类药物使用的发生率,并采用多变量逻辑回归模型确定在最初 30 天内增加新的持续性使用风险和初始围手术期处方阿片类药物再配药的风险因素。
新的持续性阿片类药物使用和再配药。
共纳入 327379 名(平均年龄 67 岁[标准差 16 岁];178067 名女性[54.4%])阿片类药物初治患者接受眼科手术。其中 14841 名(4.5%)患者接受了围手术期初始阿片类药物处方。与未接受围手术期初始阿片类药物处方的患者(0.6%[1833 例/312538 例])相比,新的持续性阿片类药物使用发生率为 3.4%(498 例/14841 例)。在调整患者特征后,围手术期初始阿片类药物处方与新的持续性使用的可能性增加独立相关(调整后的优势比[OR],6.21;95%置信区间[CI],5.57-6.91;P<0.001)。在接受初始围手术期处方的患者中,处方剂量为 150 吗啡毫克当量或更高与再配药的可能性增加相关(调整后的 OR,1.87;95% CI,1.58-2.22;P<0.001)。
在以前阿片类药物初治的患者中,围手术期接触阿片类药物与新的持续性使用相关。这表明,在接受切口性眼科手术的患者中,接触阿片类药物是持续性使用的一个独立风险因素。鉴于当前全国阿片类药物危机,外科医生应了解这些风险,以识别有风险的患者,并在可能的情况下尽量减少阿片类药物的处方。